$Cellectar(CLRB)$ Cellectar BioSciences surges 52% premarket after announcing Positive topline data achieving primary endpoint in pivotal clinical study of Iopofosine I 131 in Waldenstrom’s macroglobulinemia
| 发布于: | 雪球 | 转发：0 | 回复：0 | 喜欢：0 |
$Cellectar(CLRB)$ Cellectar BioSciences surges 52% premarket after announcing Positive topline data achieving primary endpoint in pivotal clinical study of Iopofosine I 131 in Waldenstrom’s macroglobulinemia